KB-1174

Cusatuzumab

Home » Antibody » Cusatuzumab

Background

CD70, a tumor necrosis factor receptor ligand, is a very promising target due to its consistent expression on LSC and AML blasts. In AML, the binding of CD70 to its receptor, CD27, on LSC and subsequent downstream signaling activates gene-expression profiles that promote LSC proliferation, reduce differentiation, and lead to release of soluble CD27. Cusatuzumab (ARGX-110) is a high-affinity, anti-CD70 monoclonal antibody that blocks CD70/CD27 signaling, leading to inhibition of LSC proliferation, a reduction in leukemic blast cells, blockade of regulatory T-cell survival (preventing tumor immune escape), and restoration of normal myeloid differentiation.

Specifications

Catalog Number:
KB-1174
Cell Line Name:
Cusatuzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CD70
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.?Riether C, Sch¨¹rch CM, B¨¹hrer ED, et al.. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214(2):359-380. 2.?Silence K, Dreier T, Moshir M, et al.. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014;6(2):523-532.
Please enable JavaScript in your browser to complete this form.